Studying temporal titre evolution of commercial SARS-CoV-2 assays reveals significant shortcomings of using BAU standardization for comparison

I. Kroidl, S. Winter, R. Rubio-Acero, A. Bakuli, C. Geldmacher et al.

Contributing partner:

Ludwig-Maximilian-Universität München (LMU)